Full text
Earnings transcript
Read the complete earnings call transcript.
GSK
GSK plc
$52.48
1.31
(2.56%)
| Exchange: | NYSE |
| Market Cap: | 105.192B |
| Shares Outstanding: | 2.368B |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Drug Manufacturers – General | |||||
| CEO: | Luke Victor Miels | |||||
| Full Time Employees: | 68629 | |||||
| Address: |
| |||||
| Website: | https://www.gsk.com |
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company’s operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson’s disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 30,328,000 | 31,376,000 | 32,667,000 |
| Gross Profit | 21,763,000 | 22,328,000 | 23,650,000 |
| EBITDA | 9,083,000 | 6,668,000 | 10,402,000 |
| Operating Income | 6,745,000 | 4,021,000 | 8,338,000 |
| Net Income | 4,928,000 | 2,575,000 | 5,716,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 59,005,000 | 59,463,000 | 61,010,573 |
| Total Liabilities | 46,210,000 | 46,377,000 | 45,015,737 |
| Total Stockholders Equity | 13,347,000 | 13,671,000 | 16,348,214 |
| Total Debt | 18,018,000 | 16,986,000 | 17,688,854 |
| Cash and Cash Equivalents | 2,746,000 | 3,693,000 | 3,391,029 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 6,768,000 | 6,554,000 | 7,142,957.939 |
| Capital Expenditure | -2,344,000 | -2,982,000 | -1,318,459.170 |
| Free Cash Flow | 4,424,000 | 3,572,000 | 5,824,498.768 |
| Net Income | 4,928,000 | 2,951,000 | 5,590,736.352 |
| Net Change in Cash | -567,000 | 545,000 | -206,063.061 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 48,573,667.457 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 51,564,296.619 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 50,184,041.112 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 16,271,927.889 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 17,273,773.222 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 16,811,394.752 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 5,892,373.915 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 6,368,741.693 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 6,148,883.600 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 14,674,074.578 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 15,577,541.779 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 15,160,567.453 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 5.970 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 6.190 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 5.720 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 8 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 3 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Revenue Performance: GSK has demonstrated consistent revenue generation as per the income statement data, with strong gross profit margins (grossProfitMarginTTM) indicating operational efficiency. This reflects a solid foundation in its core pharmaceutical and healthcare product segments.
- Strong Cash Flow Metrics: The cash flow statements highlight positive free cash flow (freeCashFlowTTM and freeCashFlow from recent periods), showcasing GSK’s ability to generate cash after capital expenditures, which supports dividend payments (dividendYieldTTM) and potential reinvestment in innovation.
- Global Market Presence: Revenue geographic segments data indicates diversified income streams across multiple regions, reducing dependency on a single market and enhancing resilience against localized economic downturns.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about GSK valuation
Is GSK plc (GSK) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for GSK plc (GSK) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is GSK a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether GSK trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is GSK’s P/E ratio?
You can see GSK’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for GSK?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is GSK a good long-term investment?
Whether GSK fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
GSK
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
2.56
Trading Metrics:
| Open: | 52.18 | Previous Close: | 51.17 | |
| Day Low: | 52.08 | Day High: | 52.54 | |
| Year Low: | 35.45 | Year High: | 61.7 | |
| Price Avg 50: | 53.15 | Price Avg 200: | 49.7 | |
| Volume: | 2.176M | Average Volume: | 4.082M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeGSK full analysis
Welcome to MARKETSNAP’s SWOT analysis for GlaxoSmithKline, or GSK as most of us know it (ticker symbol GSK for those just tuning in). If you’re a long-term investor looking to build wealth, you’ve likely got your eye on big players in the pharmaceutical space, and GSK is definitely one to watch. Today, we’re diving deep into what makes this company tick, breaking down its strengths, weaknesses, opportunities, and threats, while keeping an eye on both short-term trends and long-term potential.…
